TWST - Twist Bioscience Corporation
| Previous close | 16.67 |
| Open | 16.65 |
| Bid | 16.51 x 1100 |
| Ask | 16.55 x 900 |
| Day's range | 16.27 - 17.00 |
| 52-week range | 11.46 - 58.76 |
| Volume | |
| Avg. volume | 1,430,328 |
| Market cap | 953.214M |
| Beta (5Y monthly) | 1.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
We're Hopeful That Twist Bioscience (NASDAQ:TWST) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Simply Wall St.
Investors Don't See Light At End Of Twist Bioscience Corporation's (NASDAQ:TWST) Tunnel
With a price-to-sales (or "P/S") ratio of 3.2x Twist Bioscience Corporation ( NASDAQ:TWST ) may be sending very bullish...
- Zacks
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) delivered earnings and revenue surprises of 2.75% and 6.31%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Horizon Therapeutics (HZNP) Q1 Earnings and Revenues Lag Estimates
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of -29.06% and 7.16%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Motley Fool
3 Growth Stocks Cathie Wood Just Bought That Could Be Absolute Game-Changers
If there's one word you could use to describe the kinds of stocks that Cathie Wood buys, it would be "innovative." In fact, three of her ARK Invest exchange-traded funds (ETFs) include the word "innovation" in their names. Wood's flagship ARK Innovation ETF has loaded up in recent weeks on Beam Therapeutics (NASDAQ: BEAM).
- Zacks
Twist Bioscience (TWST) Expected to Beat Earnings Estimates: Should You Buy?
Twist Bioscience (TWST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool
Cathie Wood Goes Bargain-Hunting: 3 Stocks She Just Bought
The iconic money manager with a penchant for aggressive growth is staying active as her exchange-traded funds bounce back in 2023.
- Simply Wall St.
Shareholders in Twist Bioscience (NASDAQ:TWST) are in the red if they invested a year ago
Investing in stocks comes with the risk that the share price will fall. And unfortunately for Twist Bioscience...
- Zacks
Twist Bioscience (TWST) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Twist Bioscience (TWST) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- Zacks
Twist Bioscience (TWST) Upgraded to Buy: Here's Why
Twist Bioscience (TWST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Zacks
Wall Street Analysts Predict a 26.05% Upside in Twist Bioscience (TWST): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 26.1% in Twist Bioscience (TWST). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Motley Fool
Why Twist Bioscience Stock Is Sinking Today
Shares of Twist Bioscience (NASDAQ: TWST) were sinking 17.5% as of 11:18 a.m. ET on Friday. The steep decline came after the synthetic DNA maker announced its fiscal 2023 first-quarter results. Twist reported Q1 revenue of $54.2 million, up 29% year over year.
- Zacks
Twist Bioscience (TWST) Reports Q1 Loss, Misses Revenue Estimates
Twist Bioscience (TWST) delivered earnings and revenue surprises of 32.11% and 0.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Twist Bioscience (TWST) Upgraded to Buy: What Does It Mean for the Stock?
Twist Bioscience (TWST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Simply Wall St.
Twist Bioscience Full Year 2022 Earnings: EPS Beats Expectations
Twist Bioscience ( NASDAQ:TWST ) Full Year 2022 Results Key Financial Results Revenue: US$203.6m (up 54% from FY 2021...
- Zacks
Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) delivered earnings and revenue surprises of 28.91% and 0.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- Motley Fool
Why Twist Bioscience Stock Is Crashing This Week
Shares of Twist Bioscience (NASDAQ: TWST) were crashing this week, plunging 37.2% as of the market close on Thursday, according to data provided by S&P Global Market Intelligence. The steep decline came after Scorpion Capital announced on Tuesday that it was short-selling the stock and released a scathing online report about the synthetic DNA maker. Scorpion accused Twist Bioscience of being "a cash-burning inferno that is not a going concern."
- Motley Fool
Why Shares of Twist Bioscience Fell 19.92% on Tuesday
A day after synthetic biology and genomics company Twist Bioscience (NASDAQ: TWST) saw its shares rise 16.1%, they did a U-turn, falling 19.92% on Tuesday. A report issued Tuesday by Scorpion Capital sent Twist's shares plummeting. In its third-quarter report, released Aug. 5, Twist said it had $56.1 million in revenue, up 60.2%, year over year and 37.4% sequentially.
- Zacks
Twist Bioscience (TWST) Surges 16.1%: Is This an Indication of Further Gains?
Twist Bioscience (TWST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Zacks
PacBio's (PACB) Latest Offering to Enhance Genome Sequencing
PacBio's (PACB) latest sequencing panels are expected to simplify the study of the difficult-to-sequence or accurately map genomes, thereby aiding researchers.
- Simply Wall St.
The past year for Twist Bioscience (NASDAQ:TWST) investors has not been profitable
Even the best investor on earth makes unsuccessful investments. But it's not unreasonable to try to avoid truly...
- Motley Fool
Got $2,000? Consider Buying These 2 Beaten-Down Cathie Wood Stocks at Your Own Risk
Cathie Wood's ARK Innovation ETF (NYSEMKT: ARKK) is down by more than 56% this year, and it might have further to fall. In that vein, two aspiring biomedical businesses are a bit worse for the wear of the bear market despite Cathie Wood's continued confidence in their success. 10X Genomics (NASDAQ: TXG) sells laboratory analyzer devices used to profile gene expression in cells.
- Motley Fool
3 Monster Stocks in the Making
Here's why they chose Axsome Therapeutics (NASDAQ: AXSM), Exelixis (NASDAQ: EXEL), and Twist Bioscience (NASDAQ: TWST). Prosper Junior Bakiny (Axsome Therapeutics): Many qualities are necessary to be a successful investor. The case of Axsome Therapeutics somewhat illustrates that.
- Motley Fool
Why Twist Bioscience's Shares Rose 25.1% in July
Shares of Twist Bioscience (NASDAQ: TWST), a biotech company that makes synthetic DNA-based products, including synthetic genes, antibody libraries for drug development and tools for next-generation sample preparation, jumped 25.1% in July, according to according to data from S&P Global Intelligence. On July 14, the company announced that it was launching two monkeypox virus synthetic DNA controls, including the Congo Basin clade (genetic branch) from Central Africa and the West African clade. The second bit of news that helped drive up Twist's shares was that Cathie Wood's ARK Innovation ETF bought an additional 156,417 shares of Twist in July, raising the ETF's number of Twist shares to 6.27 million, making it the second-largest holder of Twist shares.
- Zacks
Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) delivered earnings and revenue surprises of 16.92% and 9.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
